A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

Published: June 23, 2009
Abstract Views: 182
PDF: 192
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Background Panobinostat (LBH589) is a potent pan-deacetylase inhibitor (DACi) which has demonstrated activity in patients (pts) with CTCL in a Phase I study (Prince et al., ASCO 2007).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Bernengo, M., Vanaclocha, F., Duvic, M., Kuzel, T., Kerdel, F., Pinter-Brown, L., Bosly, A., Okada, C., Breneman, D., Zinzani, P., Becker, J., Hughey, L., Ardaiz, M., Zain, J., & Zhang, L. (2009). A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.725